2026: Catalysts for Growth
                                                        • Complete enrollment in BROADEN2 Phase 2b AD
                                 KT-621                   study in 2026; report data by mid-2027
                                 First-in-Class Oral    • Advance BREADTH Phase 2b asthma study; report
                                 STAT6 Degrader           data in late-2027



                                 KT-579                 • Initiate Phase 1 HV trial in Q1 2026
                                 First-in-Class Oral    • Report Phase 1 HV data in 2H 2026
                                 IRF5 Degrader


                                                        • Advance at least one new development candidate
    Unlocking high value         Research                 towards IND for a first-in-class, oral immunology
                                                          program in 2026
    targets to revolutionize
    immunology
Unlocking         withtargets
          high value   oral to
                                                       • Collaborate with Sanofi to advance KT-485, oral
    degrader medicines
revolutionize  immunology        Partnered               IRAK4 degrader, into a Phase 1 clinical trial in 2026
with oral degrader medicines     Programs              • Collaborate with Gilead to advance oral CDK2
                                                         molecular glue degrader program in preclinical
                                                         studies                                                 53
